Effect of starting metformin on severe and long COVID-19 among people living with type 2 diabetes in England: a new user cohort study in OpenSAFELY-TPP

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Introduction

Observational studies report lower COVID-19 mortality among metformin users, but most used prevalent-user designs comparing long-term survivors with heterogeneous controls. Randomised trials suggest little or no mortality effect. No large observational study has used a new-user design to estimate the effect of starting versus not starting metformin on severe and Long COVID outcomes in adults with type 2 diabetes (T2D). We aimed to estimate this effect on COVID-19-related hospitalisation or death, COVID-19 diagnoses, and Long COVID among adults with T2D in England.

Research design and methods

Using OpenSAFELY-TPP linked NHS electronic health records, we conducted a population-based cohort study with a landmark new-user design. Adults aged 18-85 years newly diagnosed with T2D (August 2018-August 2019) were classified as starting metformin monotherapy within 6 months or not starting any antidiabetic drug, based on prescription data. Follow-up began 6 months after diagnosis and before the UK pandemic (avoiding immortal time) for up to 2 years. We estimated intention-to-treat and per-protocol effects using weighted Cox and pooled logistic regression, with negative (bone fracture) and positive (diabetes-related death) control outcomes.

Results

Of 52,341 eligible people, 19,599 (37.4%) started metformin. For COVID-19-related hospitalisation or death, the maximally adjusted hazard ratio (HR) of metformin versus no antidiabetic was 1.17 (95% CI 1.02-1.35; 2-year risk difference 0.36%, 95% CI 0.09-0.62; intention-to-treat). The per-protocol HR for COVID-19-related hospitalisation or death was 1.11 (95% CI 0.96-1.29). The Long COVID estimate was imprecise (HR 1.39, 95% CI 0.83-2.33; intention-to-treat). For bone fracture (negative control) the estimate was null (HR 1.00), but for diabetes-related deaths (positive control) it was elevated (HR 1.41, 95% CI 1.09-1.81), indicating unmeasured confounding.

Conclusions

The risks of severe and long COVID were slightly higher among people who started metformin, compared with those who did not start. These results plausibly reflect unmeasured confounding. These findings align more closely with randomised evidence than earlier prevalent-user studies and argue against a clinically meaningful benefit of starting metformin for COVID-19 prevention in newly diagnosed T2D.

What is already known on this topic

Observational studies and their meta-analyses have consistently reported 30-40% lower COVID-19 mortality among metformin users, yet most used prevalent-user designs that compare long-term survivors with mixed control groups and can overstate benefit. Randomised trials suggest little or no effect on mortality.

What this study adds

Using a new-user design in more than 52,000 adults with newly diagnosed T2D, risks of severe and long COVID were slightly higher among people who started metformin, compared with those who did not start. These results plausibly reflect unmeasured confounding rather than harm.

How this study might affect research, practice or policy

These findings align with randomised evidence and argue against a clinically meaningful benefit of starting metformin for preventing severe or Long COVID in people with T2D. They also illustrate how new-user designs can reconcile discrepant observational and trial results and should be prioritised in future drug-repurposing studies.

Lay summary

Metformin is a medication commonly used to treat type 2 diabetes. During the COVID-19 pandemic, some studies suggested it might also protect against severe COVID-19, but many such studies had design limitations that could have made metformin look more beneficial than it truly is. In this study, we used NHS health records from over 52,000 adults in England who were newly diagnosed with type 2 diabetes to examine whether starting metformin shortly after diagnosis reduced the risk of being hospitalised or dying from COVID-19, being diagnosed with COVID-19. We found no evidence that starting metformin protected against any of these outcomes, although the effect on long COVID was imprecisely estimated. Our findings are consistent with results from clinical trials and suggest that metformin should not be expected to prevent severe COVID-19 in people with type 2 diabetes.

Article activity feed